Form 4: Beam Therapeutics SVP Sells Shares Under 10b5-1 Plan

Bethany J Cavanagh, SVP of Finance and Treasurer at Beam Therapeutics, sold 3,034 shares of common stock for $30.12 per share under a pre-arranged trading plan.

Summary

• Bethany J Cavanagh, the Senior Vice President of Finance and Treasurer of Beam Therapeutics Inc. (BEAM), reported a transaction.
• The transaction involved the sale of 3,034 shares of Beam Therapeutics Common Stock.
• The shares were sold at a price of $30.12 per share.
• The sale occurred on January 20, 2026.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Cavanagh on September 19, 2025.
• Following this transaction, Ms. Cavanagh beneficially owns 41,011 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is a neutral event for company sentiment.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure for a biotechnology company, reflecting an individual executive's pre-planned stock sale rather than a broader industry trend or company-specific strategic move.

Stakeholder Impact

• Shareholders: Disclosure of insider trading activity provides transparency regarding management's stock holdings and trading patterns.

Key Dates

Recommendation

The filing details a pre-scheduled insider stock sale, which is a routine event and does not inherently signal a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this disclosure.

Keywords

Beam Therapeutics, BEAM, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Bethany J Cavanagh, SVP Finance, Treasurer